Literature DB >> 30550791

Organoid Modeling of the Tumor Immune Microenvironment.

James T Neal1, Xingnan Li1, Junjie Zhu2, Valeria Giangarra3, Caitlin L Grzeskowiak1, Jihang Ju1, Iris H Liu1, Shin-Heng Chiou4, Ameen A Salahudeen1, Amber R Smith1, Brian C Deutsch1, Lillian Liao1, Allison J Zemek5, Fan Zhao4, Kasper Karlsson1, Liora M Schultz6, Thomas J Metzner7, Lincoln D Nadauld1, Yuen-Yi Tseng8, Sahar Alkhairy8, Coyin Oh8, Paula Keskula8, Daniel Mendoza-Villanueva9, Francisco M De La Vega9, Pamela L Kunz6, Joseph C Liao7, John T Leppert7, John B Sunwoo10, Chiara Sabatti11, Jesse S Boehm8, William C Hahn12, Grace X Y Zheng3, Mark M Davis13, Calvin J Kuo14.   

Abstract

In vitro cancer cultures, including three-dimensional organoids, typically contain exclusively neoplastic epithelium but require artificial reconstitution to recapitulate the tumor microenvironment (TME). The co-culture of primary tumor epithelia with endogenous, syngeneic tumor-infiltrating lymphocytes (TILs) as a cohesive unit has been particularly elusive. Here, an air-liquid interface (ALI) method propagated patient-derived organoids (PDOs) from >100 human biopsies or mouse tumors in syngeneic immunocompetent hosts as tumor epithelia with native embedded immune cells (T, B, NK, macrophages). Robust droplet-based, single-cell simultaneous determination of gene expression and immune repertoire indicated that PDO TILs accurately preserved the original tumor T cell receptor (TCR) spectrum. Crucially, human and murine PDOs successfully modeled immune checkpoint blockade (ICB) with anti-PD-1- and/or anti-PD-L1 expanding and activating tumor antigen-specific TILs and eliciting tumor cytotoxicity. Organoid-based propagation of primary tumor epithelium en bloc with endogenous immune stroma should enable immuno-oncology investigations within the TME and facilitate personalized immunotherapy testing.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  PD-1; PDO; T cell receptor; TCR; cancer; checkpoint inhibitor; immunotherapy; organoid; single-cell RNA-seq; tumor-infiltrating lymphocyte

Mesh:

Substances:

Year:  2018        PMID: 30550791      PMCID: PMC6656687          DOI: 10.1016/j.cell.2018.11.021

Source DB:  PubMed          Journal:  Cell        ISSN: 0092-8674            Impact factor:   66.850


  60 in total

1.  Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients.

Authors:  Roy S Herbst; Jean-Charles Soria; Marcin Kowanetz; Gregg D Fine; Omid Hamid; Michael S Gordon; Jeffery A Sosman; David F McDermott; John D Powderly; Scott N Gettinger; Holbrook E K Kohrt; Leora Horn; Donald P Lawrence; Sandra Rost; Maya Leabman; Yuanyuan Xiao; Ahmad Mokatrin; Hartmut Koeppen; Priti S Hegde; Ira Mellman; Daniel S Chen; F Stephen Hodi
Journal:  Nature       Date:  2014-11-27       Impact factor: 49.962

2.  Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial.

Authors:  Jeffrey S Weber; Sandra P D'Angelo; David Minor; F Stephen Hodi; Ralf Gutzmer; Bart Neyns; Christoph Hoeller; Nikhil I Khushalani; Wilson H Miller; Christopher D Lao; Gerald P Linette; Luc Thomas; Paul Lorigan; Kenneth F Grossmann; Jessica C Hassel; Michele Maio; Mario Sznol; Paolo A Ascierto; Peter Mohr; Bartosz Chmielowski; Alan Bryce; Inge M Svane; Jean-Jacques Grob; Angela M Krackhardt; Christine Horak; Alexandre Lambert; Arvin S Yang; James Larkin
Journal:  Lancet Oncol       Date:  2015-03-18       Impact factor: 41.316

3.  Systemic Immunity Is Required for Effective Cancer Immunotherapy.

Authors:  Matthew H Spitzer; Yaron Carmi; Nathan E Reticker-Flynn; Serena S Kwek; Deepthi Madhireddy; Maria M Martins; Pier Federico Gherardini; Tyler R Prestwood; Jonathan Chabon; Sean C Bendall; Lawrence Fong; Garry P Nolan; Edgar G Engleman
Journal:  Cell       Date:  2017-01-19       Impact factor: 41.582

4.  T-cell invigoration to tumour burden ratio associated with anti-PD-1 response.

Authors:  Alexander C Huang; Michael A Postow; Robert J Orlowski; Rosemarie Mick; Bertram Bengsch; Sasikanth Manne; Wei Xu; Shannon Harmon; Josephine R Giles; Brandon Wenz; Matthew Adamow; Deborah Kuk; Katherine S Panageas; Cristina Carrera; Phillip Wong; Felix Quagliarello; Bradley Wubbenhorst; Kurt D'Andrea; Kristen E Pauken; Ramin S Herati; Ryan P Staupe; Jason M Schenkel; Suzanne McGettigan; Shawn Kothari; Sangeeth M George; Robert H Vonderheide; Ravi K Amaravadi; Giorgos C Karakousis; Lynn M Schuchter; Xiaowei Xu; Katherine L Nathanson; Jedd D Wolchok; Tara C Gangadhar; E John Wherry
Journal:  Nature       Date:  2017-04-10       Impact factor: 49.962

5.  Comprehensive molecular characterization of human colon and rectal cancer.

Authors: 
Journal:  Nature       Date:  2012-07-18       Impact factor: 49.962

6.  Differential Activity of Nivolumab, Pembrolizumab and MPDL3280A according to the Tumor Expression of Programmed Death-Ligand-1 (PD-L1): Sensitivity Analysis of Trials in Melanoma, Lung and Genitourinary Cancers.

Authors:  Luisa Carbognin; Sara Pilotto; Michele Milella; Vanja Vaccaro; Matteo Brunelli; Anna Caliò; Federica Cuppone; Isabella Sperduti; Diana Giannarelli; Marco Chilosi; Vincenzo Bronte; Aldo Scarpa; Emilio Bria; Giampaolo Tortora
Journal:  PLoS One       Date:  2015-06-18       Impact factor: 3.240

7.  Massively parallel digital transcriptional profiling of single cells.

Authors:  Grace X Y Zheng; Jessica M Terry; Phillip Belgrader; Paul Ryvkin; Zachary W Bent; Ryan Wilson; Solongo B Ziraldo; Tobias D Wheeler; Geoff P McDermott; Junjie Zhu; Mark T Gregory; Joe Shuga; Luz Montesclaros; Jason G Underwood; Donald A Masquelier; Stefanie Y Nishimura; Michael Schnall-Levin; Paul W Wyatt; Christopher M Hindson; Rajiv Bharadwaj; Alexander Wong; Kevin D Ness; Lan W Beppu; H Joachim Deeg; Christopher McFarland; Keith R Loeb; William J Valente; Nolan G Ericson; Emily A Stevens; Jerald P Radich; Tarjei S Mikkelsen; Benjamin J Hindson; Jason H Bielas
Journal:  Nat Commun       Date:  2017-01-16       Impact factor: 14.919

8.  A Novel Method to Generate and Expand Clinical-Grade, Genetically Modified, Tumor-Infiltrating Lymphocytes.

Authors:  Marie-Andrée Forget; René J Tavera; Cara Haymaker; Renjith Ramachandran; Shuti Malu; Minying Zhang; Seth Wardell; Orenthial J Fulbright; Chistopher Leroy Toth; Audrey M Gonzalez; Shawne T Thorsen; Esteban Flores; Arely Wahl; Weiyi Peng; Rodabe N Amaria; Patrick Hwu; Chantale Bernatchez
Journal:  Front Immunol       Date:  2017-08-02       Impact factor: 7.561

9.  Single-cell transcriptome analysis identifies distinct cell types and niche signaling in a primary gastric organoid model.

Authors:  Jiamin Chen; Billy T Lau; Noemi Andor; Susan M Grimes; Christine Handy; Christina Wood-Bouwens; Hanlee P Ji
Journal:  Sci Rep       Date:  2019-03-14       Impact factor: 4.379

10.  Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples.

Authors:  Kristian Cibulskis; Michael S Lawrence; Scott L Carter; Andrey Sivachenko; David Jaffe; Carrie Sougnez; Stacey Gabriel; Matthew Meyerson; Eric S Lander; Gad Getz
Journal:  Nat Biotechnol       Date:  2013-02-10       Impact factor: 54.908

View more
  310 in total

Review 1.  Characterizing the ecological and evolutionary dynamics of cancer.

Authors:  Nastaran Zahir; Ruping Sun; Daniel Gallahan; Robert A Gatenby; Christina Curtis
Journal:  Nat Genet       Date:  2020-07-27       Impact factor: 38.330

Review 2.  Human Colon Organoids and Other Laboratory Strategies to Enhance Patient Treatment Selection.

Authors:  Katherine A Johnson; Rebecca A DeStefanis; Philip B Emmerich; Patrick T Grogan; Jeremy D Kratz; Sarbjeet K Makkar; Linda Clipson; Dustin A Deming
Journal:  Curr Treat Options Oncol       Date:  2020-04-23

Review 3.  Emerging Biomimetic Materials for Studying Tumor and Immune Cell Behavior.

Authors:  Logan A Northcutt; Alejandra Suarez-Arnedo; Marjan Rafat
Journal:  Ann Biomed Eng       Date:  2019-10-15       Impact factor: 3.934

4.  Immunotherapy response modeling by ex-vivo organ culture for lung cancer.

Authors:  Iris Kamer; Elizabeta Bab-Dinitz; Oranit Zadok; Efrat Ofek; Teodor Gottfried; Inbal Daniel-Meshulam; Goni Hout-Siloni; Alon Ben Nun; Iris Barshack; Amir Onn; Jair Bar
Journal:  Cancer Immunol Immunother       Date:  2021-01-23       Impact factor: 6.968

Review 5.  Revolutionizing immunology with single-cell RNA sequencing.

Authors:  Haide Chen; Fang Ye; Guoji Guo
Journal:  Cell Mol Immunol       Date:  2019-02-22       Impact factor: 11.530

6.  RNase H-dependent PCR-enabled T-cell receptor sequencing for highly specific and efficient targeted sequencing of T-cell receptor mRNA for single-cell and repertoire analysis.

Authors:  Shuqiang Li; Jing Sun; Rosa Allesøe; Krishnalekha Datta; Yun Bao; Giacomo Oliveira; Juliet Forman; Roger Jin; Lars Rønn Olsen; Derin B Keskin; Sachet A Shukla; Catherine J Wu; Kenneth J Livak
Journal:  Nat Protoc       Date:  2019-07-24       Impact factor: 13.491

7.  Multiplexed drug testing of tumor slices using a microfluidic platform.

Authors:  A Folch; R C Rostomily; L F Horowitz; A D Rodriguez; Z Dereli-Korkut; R Lin; K Castro; A M Mikheev; R J Monnat
Journal:  NPJ Precis Oncol       Date:  2020-05-19

8.  Cell-type-specific signaling networks in heterocellular organoids.

Authors:  Jahangir Sufi; Petra Vlckova; Pelagia Kyriakidou; Xiao Qin; Sophie E Acton; Vivian S W Li; Mark Nitz; Christopher J Tape
Journal:  Nat Methods       Date:  2020-02-17       Impact factor: 28.547

9.  Massively parallel single-cell chromatin landscapes of human immune cell development and intratumoral T cell exhaustion.

Authors:  Ansuman T Satpathy; Jeffrey M Granja; Kathryn E Yost; Yanyan Qi; Francesca Meschi; Geoffrey P McDermott; Brett N Olsen; Maxwell R Mumbach; Sarah E Pierce; M Ryan Corces; Preyas Shah; Jason C Bell; Darisha Jhutty; Corey M Nemec; Jean Wang; Li Wang; Yifeng Yin; Paul G Giresi; Anne Lynn S Chang; Grace X Y Zheng; William J Greenleaf; Howard Y Chang
Journal:  Nat Biotechnol       Date:  2019-08-02       Impact factor: 54.908

Review 10.  Environmental exposures, stem cells, and cancer.

Authors:  Tasha Thong; Chanese A Forté; Evan M Hill; Justin A Colacino
Journal:  Pharmacol Ther       Date:  2019-07-31       Impact factor: 12.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.